MGNX
MACROGENICS INC
NASDAQ · Healthcare · Biotechnology · US
$2.31
−1.07%Nov 3, 2026, 21:44 UTC
MACROGENICS INC appointed Emil Kuriakose as a Class III director and member of its Science and Technology Committee, effective October 30, 2026.
Nov 3, 2026, 21:44 UTC
MACROGENICS INC appointed Michael Vasconcelles as a Class II director and member of its Science and Technology Committee, effective October 30, 2026.
Nov 3, 2026, 21:05 UTC
MACROGENICS INC announced the appointments of Emil Kuriakose and Michael Vasconcelles.
Source:Oct 26, 2026, 11:06 UTC
MacroGenics announced positive interim Phase 2 LINNET study data for lorigerlimab in patients with advanced clear cell gynecologic cancer.
Source:Oct 23, 2026, 13:15 UTC
MacroGenics announced positive interim Phase 1 data for MGC026 in patients with advanced solid tumors, reporting durable activity across a broad range of tumors.
Source:Oct 15, 2026, 20:05 UTC
MacroGenics announced that the first patient was dosed in the Phase 1 study of MGC030 for advanced solid tumors.
Source:Aug 13, 2026, 20:05 UTC
MacroGenics, Inc. reported its financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and pipeline progress.
Source:Aug 11, 2026, 20:05 UTC
Gilead Sciences exercised its option to exclusively license a preclinical bispecific program from MacroGenics under their 2022 collaboration agreement, triggering a $10 million payment to MacroGenics.
Source:Jul 2, 2026, 13:25 UTC
MacroGenics completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals.
Source: